CD47 Inhibitor

Magrolimab (Hu5F9-G4) is a humanized anti-CD47 antibody. Magrolimab, an IgG4 isotype, lacks ADCC function and exhibits relatively weak ADCP effector function. Magrolimab can be used for the study of malignant bone tumors and breast cancer.

RRx-001, a hypoxia-selective epigenetic agent and studied as a radio- and chem-sensitizer, triggers apoptosis and overcomes agent resistance in myeloma. RRx-001 exhibits potent anti-tumor activity with minimal toxicity. RRx-001 is a dual small molecule checkpoint inhibitor by downregulating CD47 and SIRP-α. RRx-001 is a potent inhibitor of G6PD and shows potent antimalarial activity.

Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) is an anti-mouse/rat/human CD47/IAP IgG1 monoclonal antibody. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can effectively block CD47 signaling and enhance macrophage phagocytic function. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can increase the infiltration of immune cells. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) may interfere with wound healing. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can be used for researches on cancer and inflammation conditions such as breast cancer and intestinal mucosal repair.

KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research.

Urabrelimab (SRF231) is a fully human anti-CD47 monoclonal antibody that blocks the CD47-SIRP interaction.

ADU-1805 is a humanized monoclonal IgG2 antibody, a selective, pan-allelic anti-SIRPα antibody, with a K_d value of 11.0 × 10^-9 M for hSIRPαV1. ADU-1805 binds to all known hSIRPα alleles. ADU-1805 blocks the SIRPα-CD47 interaction, promotes phagocytosis of cells, and enhances trogocytosis of cells. ADU-1805 can be used in research related to Burkitt lymphoma.

VxP037 is a humanized anti-CD47 antibody. The isotype control for VxP037 is Human IgG1 kappa, Isotype Control (HY-P99001).

Anzurstobart (CC-95251; BMS-986351) is a CD47/SIRPα inhibitor with human SIRPα K_d of 0.0541 nM and human SIRPα IC₅₀ of 100 nM. Anzurstobart binds SIRPα at a CD47-overlapping site, blocks CD47-SIRPα interactions, inhibits CD47-SIRPα axis signaling, and binds across 6 prevalent human SIRPα haplotypes. Anzurstobart binds SIRPγ and inhibits CD47-SIRPγ interactions. Anzurstobart can be used for the research of non-Hodgkin's lymphoma, colorectal cancer, squamous cell carcinoma of the head and neck, diffuse large B-cell lymphoma, and advanced solid and hematologic malignancies.

Anti-CD47 Antibody (B6.H12) is a kind of mouse IgG1 κ chimeric antibody, targeting to human CD47. Anti-CD47 Antibody (B6.H12) blocks CD47 interactions with SIRPα. Anti-CD47 Antibody (B6.H12) inhibits cell proliferation, cell migration and invasion. Anti-CD47 Antibody (B6.H12) increases macrophage phagocytosis. Anti-CD47 Antibody (B6.H12) shows potent anti-tumor effect in various tumor models, such as osteosarcoma.

Anti-Mouse CD47/IAP Antibody (MIAP301) is an anti-mouse CD47/IAP IgG2a monoclonal antibody. Anti-Mouse CD47/IAP Antibody (MIAP301) can effectively block CD47 signaling and enhance macrophage phagocytic function. Anti-Mouse CD47/IAP Antibody (MIAP301) can increase the infiltration of immune cells. Anti-Mouse CD47/IAP Antibody (MIAP301) restores the phagocytic function of myeloid cells and alleviate B cell inhibition. Anti-Mouse CD47/IAP Antibody (MIAP301) may interfere with wound healing. Anti-Mouse CD47/IAP Antibody (MIAP301) can be used for researches on cancer, inflammation and infection conditions such as melanoma, intestinal mucosal repair and sepsis.

Lemzoparlimab (TJ011133; TJC4) is a humanized anti-CD47 IgG4 antibody. Lemzoparlimab has a strong anti-tumor activity.

Evorpacept (ALX148) is a high-affinity CD47-blocking fusion protein with an inactive human immunoglobulin Fc region. Evorpacept binds to CD47, blocks the interaction of the CD47-SIRPα immune checkpoint, and inhibits the binding of wild-type SIRPα to CD47. Evorpacept is applicable to research related to acute myeloid leukemia.

Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity.

Thrombospondin-1 (1016-1023) (human, bovine, mouse), is the C-terminal end of the native sequence of Thrombospondin-1 (TSP-1), is a CD47 agonist peptide.

CC-90002 is a humanized anti-CD47 monoclonal antibody (mAb). CC-90002 has a high affinity for binding to CD47 with a subnanomolar K_d value. CC-90002 can be used for the research of hematologic malignancies and solid tumors.

Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity.

NCGC00138783 TFA is a selective inhibitor targeting CD47/SIRPα axis, with an IC₅₀ of 50 μM. NCGC00138783 TFA directly blocks the interaction between CD47 and SIRPα axis.

BI-765063 (OSE-172) is a humanized antibody expressed in CHO that targets SIRPa/CD172a. BI-765063 contains an IgG4-type heavy chain and a huκ-type light chain, with a predicted molecular weight (MW) of 146.3 kDa. The isotype control for BI-765063 can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).

Simridarlimab (IBI-322) is a bispecific antibody targeting PD-L1 and CD47. Simridarlimab attenuates CD47 activity in monovalent binding and blockes PD-L1 activity in bivalent binding. Simridarlimab selectively binds to CD47+PD-L1+ tumor cells, effectively inhibits CD47-SIRPα signal and triggered strong tumor cell phagocytosis in vitro.

RS17 is an anti-tumor peptide designed to bind specifically to the CD47 molecule and block the interaction between CD47 and its ligand, SIRPα, on the surface membrane of macrophages. The main regulatory mechanism of RS17 is to prevent CD47 from transmitting selective phagocytosis signals to SIRPα by binding to CD47, so that macrophages do not recognize tumor cells as their own tissue, but phagocytose them as foreign substances, thereby inhibiting immune escape of tumor cells. RS17 can be used to study the mechanism of anti-tumor response and immune escape.